

Applicants: Sharon Cohen-Vered, et al.  
Serial No.: 10/758,572  
Filed : January 14, 2004  
Page : 2

**Amendments to the Claims**

The following listing of claims will replace all prior versions, and listings, of claims in the application:

1. (Original) A pharmaceutical composition comprising  
an aqueous carrier;  
from 0.1 mg/ml to 20 mg/ml of the composition of a  
pharmaceutically acceptable salt of a peptide having the  
structural formula  
NH<sub>2</sub>-Gly Tyr Tyr Trp Ser Trp Ile Arg Gln Pro Pro Gly Lys Gly Glu  
Glu Trp Ile Gly-COOH (SEQ ID NO:1); and  
  
a substituted  $\beta$ -cyclodextrin in an amount effective to  
dissolve the peptide in the aqueous carrier,  
wherein the composition has a pH between 4 and 9.
2. (Original) The pharmaceutical composition of claim 1, wherein  
the concentration of the salt of the peptide is at least 0.5  
mg/ml.
3. (Original) The pharmaceutical composition of claim 2, wherein  
the concentration of the salt of the peptide is from 0.5  
mg/ml to 10 mg/ml.
4. (Original) The pharmaceutical composition of claim 3, wherein  
the concentration of the salt of the peptide is from 0.5  
mg/ml to 2.5 mg/ml.
5. (Original) The pharmaceutical composition of claim 1 wherein  
the composition has a pH between 6.5 and 8.5.
6. (Original) The pharmaceutical composition of claim 5, wherein  
the composition has a pH between 7.5 and 8.5.

Applicants: Sharon Cohen-Vered, et al.  
Serial No.: 10/758,572  
Filed : January 14, 2004  
Page : 3

7. (Original) The pharmaceutical composition claim 1 wherein the pharmaceutically acceptable salt is an acetate salt.
8. (Original) The pharmaceutical composition of claim 1 wherein the substituted  $\beta$ -cyclodextrin is a hydroxypropyl, a sulfobutyl ether, or a sulfopropyl ether substituted  $\beta$ -cyclodextrin.
9. (Original) The pharmaceutical composition of claim 8, wherein the substituted  $\beta$ -cyclodextrin is a sulfobutyl ether substituted  $\beta$ -cyclodextrin.
10. (Original) The pharmaceutical composition of claim 7, wherein the substituted  $\beta$ -cyclodextrin is hepta-(sulfobutyl ether)- $\beta$ -cyclodextrin.
11. (Original) The pharmaceutical composition of claim 1 further comprising a pharmaceutically acceptable buffer in an amount and of a type suitable to make the pH of the pharmaceutical composition in the range of 4-9.
12. (Original) A pharmaceutical composition comprising  
an aqueous carrier;  
from 0.1 mg/ml to 20 mg/ml of the composition of an acetate salt of a peptide having the structural formula  
NH<sub>2</sub>-Gly Tyr Tyr Trp Ser Trp Ile Arg Gln Pro Pro Gly Lys Gly Glu Glu  
Trp Ile Gly-COOH (SEQ ID NO:1); and  
from 70 mg/ml to 170 mg/ml of the composition of hepta-(sulfobutyl ether)- $\beta$ -cyclodextrin,  
wherein the peptide and the hepta-(sulfobutyl ether)- $\beta$ -cyclodextrin are dissolved in the aqueous carrier; and  
wherein the composition has a pH between 6.5 and 8.5.

Applicants: Sharon Cohen-Vered, et al.  
Serial No.: 10/758,572  
Filed : January 14, 2004  
Page : 4

13. (Original) The pharmaceutical composition of claim 12, wherein the concentration of the acetate salt of the peptide is at least 0.5 mg/ml.
14. (Original) The pharmaceutical composition of claim 13, wherein the concentration of the acetate salt of the peptide is from 0.5 mg/ml to 10 mg/ml.
15. (Original) The pharmaceutical composition of claim 13, wherein the concentration of the acetate salt of the peptide is from 0.5 to 2.5 mg/ml.
16. (Original) The pharmaceutical composition of claim 13, wherein the concentration of hepta-(sulfobutyl ether)- $\beta$ -cyclodextrin is 120 mg/ml, and wherein the pH of the composition is between 7.5 and 8.5.
17. (Original) The pharmaceutical composition of claim 16, wherein the concentration of the acetate salt of the peptide is 1.0 mg/ml.
18. (Original) The pharmaceutical composition of claim 16, wherein the concentration of the acetate salt of the peptide is 2.5 mg/ml.
19. (Original) A method of alleviating symptoms of systemic lupus erythematosus (SLE) in a human subject comprising administering to the human subject the pharmaceutical composition of claim 1 in an amount effective to alleviate the symptoms of SLE in the human subject.
20. (Canceled)

Applicants: Sharon Cohen-Vered, et al.  
Serial No.: 10/758,572  
Filed : January 14, 2004  
Page : 5

21. (Original) A process for manufacturing the pharmaceutical composition of claim 1 comprising the steps of:

- a) preparing a solution of a substituted  $\beta$ -cyclodextrin in an aqueous carrier at a predetermined concentration;
- b) adding a predetermined amount of a pharmaceutically acceptable salt of the peptide  $\text{NH}_2\text{-Gly Tyr Tyr Trp Ser Trp Ile Arg Gln Pro Pro Gly Lys Gly Glu Glu Trp Ile Gly-COOH}$  (SEQ ID NO:1) to the solution of step a);
- c) adjusting the pH of the solution of step b) until the peptide dissolves in the solution; and
- d) if necessary, adjusting the pH of the solution of step c) to a pH of 4-9, thereby manufacturing the pharmaceutical composition.

Claims 22-30. (Canceled)

31. (Original) A pharmaceutical composition prepared by the process of claim 21.

32. (Original) A process of lyophilizing the pharmaceutical composition of claim 2, comprising the steps of:

- a) lowering the temperature of the pharmaceutical composition to  $-40^\circ\text{C}$ ;
- b) holding the temperature at  $-40^\circ\text{C}$  for a predetermined time;
- c) raising the temperature of the solution to  $20^\circ\text{C}$ ;
- d) holding the temperature at  $20^\circ\text{C}$  for a predetermined time; and
- e) reducing the pressure and holding the temperature at  $20^\circ\text{C}$  for a predetermined time, thereby lyophilizing the pharmaceutical composition.

Applicants: Sharon Cohen-Vered, et al.  
Serial No.: 10/758,572  
Filed : January 14, 2004  
Page : 6

Claims 33-40. (Canceled)

41. (Original) The process of claim 32, wherein  
step a) is performed within 2 hours;  
step b) is performed within 3 hours;  
step c) is performed over 13 hours and at a pressure  
of 110µbar;  
step d) is performed over 13 hours and at a pressure  
of 110µbar; and  
step e) is performed over 5 hours and the pressure  
is reduced to 10µbar.

42. (Original) A lyophilized pharmaceutical composition prepared  
by the process of claim 32.

43. (Original) A process of lyophilizing the pharmaceutical  
composition of claim 2, comprising the steps of:  
a) lowering the temperature of the pharmaceutical composition  
to -45°C;  
b) holding the temperature at -45°C for a predetermined time;  
c) raising the temperature of the solution to -20°C;  
d) raising the temperature of the solution to 25°C; and  
e) holding the temperature at 25°C for a predetermined time,  
thereby lyophilizing the pharmaceutical composition.

Claims 44-51. (Canceled)

52. (Original) The process of claim 43, wherein  
step a) is performed within 6 hours;  
step b) is performed within 3 hours;  
step c) is performed over 19 hours and at a pressure  
of 150µbar;  
step d) is performed over 13 hours and at a pressure

Applicants: Sharon Cohen-Vered, et al.  
Serial No.: 10/758,572  
Filed : January 14, 2004  
Page : 7

of 150µbar; and

step e) is performed over 8 hours and at a pressure of 150µbar.

53. (Original) A lyophilized pharmaceutical composition prepared by the process of claim 43.

Claims 54-56. (Canceled)

57. (Original) A lyophilized pharmaceutical composition comprising a pharmaceutically acceptable salt of a peptide having the structural formula

NH<sub>2</sub>-Gly Tyr Tyr Trp Ser Trp Ile Arg Gln Pro Pro Gly Lys Gly Glu  
Glu Trp Ile Gly-COOH (SEQ ID NO:1); and  
a substituted β-cyclodextrin.

58. (Original) A packaged pharmaceutical composition comprised of:  
a packaging material; and  
a predetermined amount of the lyophilized pharmaceutical composition of claim 57.

59. (New) The lyophilized pharmaceutical composition of claim 53,  
wherein the water content of the composition is less than 5%.

60. (New) The lyophilized pharmaceutical composition of claim 59,  
wherein the water content of the composition is less than 4.0%.

61. (New) The lyophilized pharmaceutical composition of claim 60,  
wherein the water content of the composition is less than 3.5%.